NCT04015570 is a NA clinical trial of High Volume Plasma Exchange in Chronic Liver Disease, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT04015570?

NCT04015570 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT04015570?

Interventions in NCT04015570: High Volume Plasma Exchange, Standard Medical Treatment.

What condition does NCT04015570 study?

NCT04015570 studies Chronic Liver Disease.

Is NCT04015570 still recruiting?

NCT04015570 is currently status unknown. Last updated 11 July 2019.

Last reviewed 2019-07-11 · How we verify

NCT04015570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Plasma Exchange Compared to Standard Medical Therapy in Patients With Severe Drug Induced Liver Injury With or Without Underlying Chronic Liver Disease.

Status unknown NA Last updated 11 July 2019

What this trial tests

NA trial testing High Volume Plasma Exchange in Chronic Liver Disease in 30 participants. Status unknown.

Timeline

9 July 2019

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	9 July 2019
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across India

Drugs / interventions tested

High Volume Plasma Exchange — full drug profile →
Standard Medical Treatment — full drug profile →

Conditions studied

Chronic Liver Disease — all drugs for Chronic Liver Disease →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 70, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this randomized study subject will be randomized into two groups Group A will receive Standard Medical Treatment (Albumin + High Caloric Diet) Group B will continue Standard Medical Treatment with High Volume Plasma Exchange. All other interventions will be at the discretion of clinicians.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Epidemiology of non-alcoholic fatty liver disease in Asia.
Wong SW, Chan WK. · · 2020 · cited 47× · PMID 32152903 · DOI 10.1007/s12664-020-01018-x
61st Annual Conference of Indian Society of Gastroenterology, Virtual Diamond Jubilee ISGCON 2020, 19-20th December 2020.
· 2020 · PMID 33738693 · DOI 10.1007/s12664-020-01133-9

Verify or expand the search:

Other trials of High Volume Plasma Exchange

Trials testing the same drug.

NCT02719210 — High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure · NA · completed

Other recruiting trials for Chronic Liver Disease

Currently open trials in the same condition.

NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04015570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 11 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04015570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing